Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-24T00:57:30.306Z Has data issue: false hasContentIssue false

Chapter 16 - Cannabis Causes Positive, Negative, and Cognitive Symptoms and Produces Impairments in Electrophysiological Indices of Information Processing

from Part V - Cannabis and Psychosis

Published online by Cambridge University Press:  12 May 2023

By
Ashley M. Schnakenberg Martin ,
Mohini Ranganathan  and
Deepak Cyril D’Souza
Edited by
Deepak Cyril D'Souza ,
David Castle  and
Sir Robin Murray
Deepak Cyril D'Souza
Affiliation:
Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine
David Castle
Affiliation:
University of Tasmania, Australia
Sir Robin Murray
Affiliation:
Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
Get access

Summary

Converging lines of pre-clinical, epidemiological, and experimental evidence support an association between cannabis, cannabinoid agonists, and psychosis (see Chapters 14 and 15). The earliest anecdotal reports on observations between the use of cannabis and subsequent psychosis have been validated by a rich literature of longitudinal studies and more recently experimental studies in humans using a wide array of subjective, cognitive, and electrophysiological outcomes relevant to psychosis. This chapter provides an overview of the subjective psychotic phenomena associated with cannabis and cannabinoids and expands on more objective cognitive and psychophysiological cannabis-related effects pertinent to psychosis.

Keywords

cannabispsychosispositive symptomsnegative symptomscognitive symptomselectrophysiologyinformation processing
Type
Chapter
Information
Marijuana and Madness , pp. 156 - 166
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Arendt, M., Rosenberg, R., Foldager, L., et al. (2005). Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases. Br J Psychiatry, 187, 510–515.CrossRefGoogle ScholarPubMed
Asbridge, M., Hayden, J. A., and Cartwright, J. L. (2012). Acute cannabis consumption and motor vehicle collision risk: Systematic review of observational studies and meta-analysis. BMJ, 344, e536.Google Scholar
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., et al. (2010a). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35, 764–774.Google Scholar
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., et al. (2010b). Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35, 764–774.CrossRefGoogle ScholarPubMed
Bloomfield, M. A. P., Hindocha, C., Green, S. F., et al. (2019). The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacol Ther, 195, 132–161.CrossRefGoogle ScholarPubMed
Böcker, K. B., Hunault, C. C., Gerritsen, J., et al. (2010). Cannabinoid modulations of resting state EEG theta power and working memory are correlated in humans. J Cogn Neurosci, 22, 1906–1916.CrossRefGoogle ScholarPubMed
Bosker, W. M., Kuypers, K. P., Theunissen, E. L., et al. (2012). Medicinal Δ9‐tetrahydrocannabinol (dronabinol) impairs on‐the‐road driving performance of occasional and heavy cannabis users but is not detected in standard field sobriety tests. Addiction, 107, 1837–1844.Google Scholar
Broyd, S. J., Greenwood, L.-M., Van Hell, H. H., et al. (2016a). Mismatch negativity and P50 sensory gating in abstinent former cannabis users. Neural Plasticity, 2016, 6526437.CrossRefGoogle ScholarPubMed
Broyd, S. J., Van Hell, H. H., Beale, C., et al. (2016b). Acute and chronic effects of cannabinoids on human cognition: A systematic review. Biol Psychiatry, 79, 557–567.CrossRefGoogle ScholarPubMed
Chang, L., Yakupov, R., Cloak, C., et al. (2006). Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain, 129, 1096–1112.Google Scholar
Chopra, G. S., and Smith, J. W. (1974). Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry, 30, 24–27.Google Scholar
Cortes-Briones, J., Cahill, J. D., Skosnik, P. D., et al. (2015a). The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans. Biol Psychiatry, 78, 805–13.CrossRefGoogle ScholarPubMed
Cortes-Briones, J., Skosnik, P. D., Mathalon, D., et al. (2015b). Δ 9-THC disrupts gamma (γ)-band neural oscillations in humans. Neuropsychopharmacology, 40, 2124–2134.CrossRefGoogle ScholarPubMed
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry, 57, 594–608.Google Scholar
D’Souza, D. C., Fridberg, D. J., Skosnik, P. D., et al. (2012). Dose-related modulation of event-related potentials to novel and target stimuli by intravenous [delta]9-THC in humans. Neuropsychopharmacology, 37, 1632–1646.Google Scholar
D’Souza, D. C., Perry, E., MacDougall, L., et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29, 1558–1572.Google Scholar
Dissanayake, D. W., Zachariou, M., Marsden, C. A., et al. (2008). Auditory gating in rat hippocampus and medial prefrontal cortex: Effect of the cannabinoid agonist WIN55, 212-2. Neuropharmacology, 55, 1397–1404.Google Scholar
Englund, A., Morrison, P. D., Nottage, J., et al. (2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol, 27, 19–27.Google Scholar
Freeman, D., Dunn, G., Murray, R. M., et al. (2015). How cannabis causes paranoia: Using the intravenous administration of ∆-9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull, 41, 391–399.CrossRefGoogle ScholarPubMed
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., et al. (2009a). Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry, 66, 95–105.Google Scholar
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., et al. (2009b). Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry, 66, 95–105.Google Scholar
Gage, S. H., Jones, H. J., Burgess, S., et al. (2017). Assessing causality in associations between cannabis use and schizophrenia risk: A two-sample Mendelian randomization study. Psychol Med, 47, 971–980.CrossRefGoogle Scholar
Ganesh, S., Cortes-Briones, J., Ranganathan, M., et al. (2020). Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol: A mega analysis of individual participant-data from human laboratory studies. Int J Neuropsychopharmacol, 23, 559–570.CrossRefGoogle ScholarPubMed
Greenwood, L.-M., Broyd, S. J., Croft, R., et al. (2014). Chronic effects of cannabis use on the auditory mismatch negativity. Biol Psychiatry, 75, 449–458.Google Scholar
Greenwood, L.-M., Broyd, S. J., Van Hell, H. H., et al. (2021). Acute effects of Δ9-tetrahydrocannabinol and cannabidiol on auditory mismatch negativity. Psychopharmacology, 239, 1409–1424.Google Scholar
Gupta, S., De Aquino, J. P., D’Souza, D. C., et al. (2019). Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: A responder analysis. Psychopharmacology, 236, 2635–2640.Google Scholar
Helle, S., Løberg, E.-M., Gjestad, R., et al. (2017). The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. Psychiatry Res, 250, 92–98.CrossRefGoogle Scholar
Henquet, C., Rosa, A., Krabbendam, L., et al. (2006). An experimental study of catechol-O-methyltransferase Val158Met moderation of Δ-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology, 31, 2748–2757.Google Scholar
Hirst, R., Vaughn, D., Arastu, S., et al. (2021). Female sex as a protective factor in the effects of chronic cannabis use on verbal learning and memory. J Int Neuropsychol Soc, 27, 581–591.Google Scholar
Iseger, T. A., and Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res, 162, 153–161.Google Scholar
Juckel, G., Roser, P., Nadulski, T., et al. (2007). Acute effects of Δ 9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res, 97, 109–117.Google Scholar
Kleinloog, D., Liem-Moolenaar, M., Jacobs, G., et al. (2012). Does olanzapine inhibit the psychomimetic effects of Δ9-tetrahydrocannabinol? J Psychopharmacol, 26, 1307–1316.CrossRefGoogle ScholarPubMed
Kurzthaler, I., Hummer, M., Miller, C., et al. (1999). Effect of cannabis use on cognitive functions and driving ability. J Clin Psychiatry, 60, 395–399.Google Scholar
Liguori, A., Gatto, C. P., and Jarrett, D. B. (2002). Separate and combined effects of marijuana and alcohol on mood, equilibrium and simulated driving. Psychopharmacology, 163, 399–405.Google Scholar
Meier, M. H., Caspi, A., Ambler, A., et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci, 109, E2657–E2664.Google Scholar
Morie, K. P., Wu, J., Potenza, M. N., et al. (2021). Daily cannabis use in adolescents who smoke tobacco is associated with altered late-stage feedback processing: A high-density electrical mapping study. J Psychiatr Res, 139, 82–90.Google Scholar
Morrison, P., and Stone, J. (2011). Synthetic delta‐9‐tetrahydrocannabinol elicits schizophrenia‐like negative symptoms which are distinct from sedation. Human Psychopharmacol Clin Exp, 26, 77–80.Google Scholar
Morrison, P., Zois, V., McKeown, D., et al. (2009). The acute effects of synthetic intravenous Δ 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med, 39, 1607–1616.Google Scholar
Murray, R. M., Englund, A., Abi-Dargham, A., et al. (2017). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 124, 89–104.Google Scholar
Murray, R. M., Mehta, M., and Di Forti, M. (2014). Different dopaminergic abnormalities underlie cannabis dependence and cannabis-induced psychosis. Biol Psychiatry, 6, 430–431.Google Scholar
Näätänen, R., Paavilainen, P., Rinne, T., et al. (2007). The mismatch negativity (MMN) in basic research of central auditory processing: a review. Clin Neurophysiol, 118, 2544–2590.Google Scholar
Niemi-Pynttäri, J. A., Sund, R., Putkonen, H., et al. (2013). Substance-induced psychoses converting into schizophrenia: A register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry, 74, 20155.Google Scholar
O’Donnell, B. F., and Mackie, K. (2014). The mismatch negativity: A translational probe of auditory processing in cannabis users. Biol Psychiatry, 75, 428–429.CrossRefGoogle ScholarPubMed
O’Tuathaigh, C. M., Clarke, G., Walsh, J., et al. (2012). Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int J Neuropsychopharmacol, 15, 1331–1342.Google Scholar
Patel, S., Khan, S., Saipavankumar, M., et al. (2020). The association between cannabis use and schizophrenia: Causative or curative? A systematic review. Cureus, 12, e9303.Google ScholarPubMed
Patrick, G., and Struve, F. A. (2000). Reduction of auditory P50 gating response in marihuana users: Further supporting data. Clin Electroencephalogr, 31, 88–93.CrossRefGoogle ScholarPubMed
Pennypacker, S. D., and Romero‐Sandoval, E. A. (2020). CBD and THC: Do they complement each other like yin and yang? Pharmacotherapy, 40, 1152–1165.Google Scholar
Radhakrishnan, R., Skosnik, P. D., Cortes-Briones, J., et al. (2015). GABA deficits enhance the psychotomimetic effects of Δ9-THC. Neuropsychopharmacology, 40, 2047–2056.CrossRefGoogle ScholarPubMed
Radhakrishnan, R., Wilkinson, S. T., and D’Souza, D. C. (2014). Gone to pot: A review of the association between cannabis and psychosis. Front Psychiatry, 5, 54.Google Scholar
Ranganathan, M., and D’Souza, D. (2006). The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology, 188, 425–444.Google Scholar
Ranganathan, M., De Aquino, J. P., Cortes-Briones, J. A., et al. (2019). Highs and lows of cannabinoid-dopamine interactions: Effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans. Psychopharmacology, 236, 3209–3219.Google Scholar
Rentzsch, J., Buntebart, E., Stadelmeier, A., et al. (2011). Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects. Schizophr Res, 130, 222–227.Google Scholar
Roser, P., Della, B., Norra, C., et al. (2010). Auditory mismatch negativity deficits in long-term heavy cannabis users. Eur Arch Psychiatry Clin Neurosci, 260, 491–498.Google Scholar
de la Salle, S., Inyang, L., Impey, D., et al. (2019). Acute separate and combined effects of cannabinoid and nicotinic receptor agonists on MMN-indexed auditory deviance detection in healthy humans. Pharmacol Biochem Behav, 184, 172739.Google Scholar
Schnakenberg Martin, A. M., Bonfils, K. A., Davis, B. J., et al. (2016). Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis. Schizophr Res Cogn, 6, 15–21.Google Scholar
Schnakenberg Martin, A. M., D’Souza, D. C., Newman, S. D., et al. (2021). Differential cognitive performance in females and males with regular cannabis use. J Int Neuropsychol Soc, 27, 570–580.Google Scholar
Seely, K. A., Lapoint, J., Moran, J. H., et al. (2012). Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuro-Psychopharmacol Biol Psychiatry, 39, 234–243.Google Scholar
Sewell, R. A., Schnakenberg, A., Elander, J., et al. (2013). Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology, 226, 401–413.Google Scholar
Sewell, R. A., Skosnik, P. D., Garcia-Sosa, I., et al. (2010). Behavioral, cognitive and psychophysiological effects of cannabinoids: Relevance to psychosis and schizophrenia. Revista Brasileira de Psiquiatria, 32, 515–530.CrossRefGoogle ScholarPubMed
Sherif, M., Radhakrishnan, R., D’Souza, D. C., et al. (2016). Human laboratory studies on cannabinoids and psychosis. Biol Psychiatry, 79, 526–538.Google Scholar
Skosnik, P. D., Cortes-Briones, J. A., and Hajós, M. (2016). It’s all in the rhythm: The role of cannabinoids in neural oscillations and psychosis. Biol Psychiatry, 79, 568–577.Google Scholar
Skosnik, P. D., D’Souza, D. C., Steinmetz, A. B., et al. (2012). The effect of chronic cannabinoids on broadband EEG neural oscillations in humans. Neuropsychopharmacology, 37, 2184–2193.Google Scholar
Skosnik, P. D., Hajós, M., Cortes-Briones, J. A., et al. (2018). Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans. Neuropharmacology, 135, 412–423.CrossRefGoogle ScholarPubMed
Skosnik, P. D., Krishnan, G. P., Aydt, E. E., et al. (2006). Psychophysiological evidence of altered neural synchronization in cannabis use: Relationship to schizotypy. Am J Psychiatry, 163, 1798–1805.Google Scholar
Skosnik, P. D., Krishnan, G. P., D’Souza, D. C., et al. (2014). Disrupted gamma-band neural oscillations during coherent motion perception in heavy cannabis users. Neuropsychopharmacology, 39, 3087–3099.Google Scholar
Spaderna, M., Addy, P. H., and D’Souza, D. C. (2013). Spicing things up: Synthetic cannabinoids. Psychopharmacology, 228, 525–540.Google Scholar
Stoller, K., Swanson, G. D., and Bellville, J. W. (1976). Effects on visual tracking of δ9‐tetrahydrocannabinol and pentobarbital. J Clin Pharmacol, 16, 271–275.Google Scholar
Stringer, S., Minică, C., Verweij, K. J., et al. (2016). Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium. Transl Psychiatry, 6, e769.Google Scholar
Umbricht, D., Koller, R., Schmid, L., et al. (2003). How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry, 53, 1120–1131.Google Scholar
Vaucher, J., Keating, B. J., Lasserre, A. M., et al. (2018). Cannabis use and risk of schizophrenia: A Mendelian randomization study. Mol Psychiatry, 23, 1287–1292.Google Scholar
Volkow, N. D., Swanson, J. M., Evins, A. E., et al. (2016). Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: A review. JAMA Psychiatry, 73, 292–297.Google Scholar
Weinstein, A., Brickner, O., Lerman, H., et al. (2008). Brain imaging study of the acute effects of Δ9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology, 196, 119–131.Google Scholar
Yang, G. J., Murray, J. D., Repovs, G., et al. (2014). Altered global brain signal in schizophrenia. Proc Natl Acad Sci USA, 111, 7438–7443.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×